Gut microbiota in patients with locally advanced cutaneous melanoma as a predictor of response to immunotherapy aPD1

cancer [Reference1].In that instance, UVB phototherapy and topical corticosteroids managed the condition, allowing continued immunotherapy.Our case and this latest one demonstrates the efficacy of dermatological interventions in managing immunotherapy-induced psoriasis without treatment interruption.A meta-analysis of 232 oncological patients treated with anti-PD-L1 therapy also documented other cutaneous adverse effects, including maculopapular eruptions, vitiligo, and Stevens-Johnson syndrome, illustrating the diverse dermatological complications of immunotherapy. [Reference2]Conclusions: This case highlights the importance of multidisciplinary cooperation in oncology, particularly in managing immunemediated cutaneous adverse events associated with immunotherapy.The integration of dermatological expertise in cancer care allows for early recognition, accurate diagnosis, and appropriate treatment of skin reactions, enabling the continuation of cancer therapy.